# US 2008/0306142 A1 · Isolation, purification and synthesis of procyanidin B2 and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0306142 A1
- Document ID: US20080306142A1
- Status: Published application
- Kind: A1
- Application number: 12/119,212
- Filed: 2008-05-12
- Published: 2008-12-11
- Earliest claimed: 2002-10-11
- Assignees: Proteotech, Inc.
- Inventors: Gerardo Castillo; Beth Nguyen; Paula Choi; Lesley Larsen; Stephen Lorimer; Alan Snow
- Web page: https://patentgrep.com/patent/US20080306142A1

## CPC

- C07D 407/04: directly linked by a ring-member-to-ring-member bond
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/08: of the prostate
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- A61P 35/00: Antineoplastic agents
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C07D 311/62: with oxygen atoms directly attached in position 3, e.g. anthocyanidins
- C07D 321/10: condensed with carbocyclic rings or ring systems
- C07D 323/00: Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods for the synthesis, isolation, and purification of procyanidin B2 are disclosed. The synthetic methods utilize epicatechin as a starting material and produce procyanidin B2 in high yields. The isolation methods extract procyanidin B2 from a sample of bark powder from plant matter of the genus Uncaria. The isolated and/or synthesized procyanidin B2 is used to treat amyloid disease, such as Alzheimer's disease and Parkinson's disease as well as improve cognitive performance and increase learning and memory in Alzheimer's patients. Pharmaceutical compositions containing the synthesized and/or isolated procyanidin B2 are also disclosed.

## Claims

### Claim 1

A method for improving cognitive performance and/or slowing cognitive decline in a patient suffering from an amyloid disease comprising administering a therapeutically effective amount of a procyanidin B2 to reduce formation, deposition, accumulation, or persistence of beta-amyloid protein fibrils in the patient wherein the amount of the procyanidin B2 administered is between about 0.1 mg/kg of body weight and about 1000 mg/kg of body weight of the patient per day.

### Claim 2 (depends on 1)

The method of claim 1, wherein the amount of the procyanidin B2 administered is between about 1 mg/kg of body weight per day and about 100 mg/kg of body weight per day.

### Claim 3 (depends on 1)

The method of claim 1, wherein the amount of the procyanidin B2 administered is between about 10 mg/kg of body weight per day and about 100 mg/kg of body weight per day.

### Claim 4

A method for improving learning and/or memory in an Alzheimer's patient comprising administering a therapeutically effective amount of a procyanidin B2 to reduce formation, deposition, accumulation, or persistence of beta-amyloid protein fibrils in the patient, wherein the amount of the procyanidin B2 administered is between about 0.1 mg/kg of body weight and about 1000 mg/kg of body weight of the patient per day.

### Claim 5 (depends on 5)

The method of claim 5, wherein the amount of the procyanidin B2 administered is between about 1 mg/kg of body weight per day and about 100 mg/kg of body weight per day.

### Claim 6 (depends on 5)

The method of claim 5, wherein the amount of the procyanidin B2 administered is between about 10 mg/kg of body weight per day and about 100 mg/kg of body weight per day.

### Claim 7

A method for improving cognitive performance and/or slowing cognitive decline in a patient suffering from an amyloid disease comprising administering a therapeutically effective amount of a procyanidin B2 wherein the amount of the procyanidin B2 administered is between about 0.1 mg/kg of body weight and about 1000 mg/kg of body weight of the patient per day.

### Claim 8 (depends on 7)

The method of claim 7, wherein the amount of the procyanidin B2 administered is between about 1 mg/kg of body weight per day and about 100 mg/kg of body weight per day.

### Claim 9 (depends on 7)

The method of claim 7, wherein the amount of the procyanidin B2 administered is between about 10 mg/kg of body weight per day and about 100 mg/kg of body weight per day.
